

# National Board of Examinations

<b>Question Paper Name :</b>	DNB Pharmacology Paper1
<b>Subject Name :</b>	DNB Pharmacology Paper1
<b>Creation Date :</b>	2024-10-17 16:12:22
<b>Duration :</b>	180
<b>Total Marks :</b>	100
<b>Display Marks:</b>	No
<b>Share Answer Key With Delivery Engine :</b>	No
<b>Actual Answer Key :</b>	No

## DNB Pharmacology Paper1

<b>Group Number :</b>	1
<b>Group Id :</b>	3271872822
<b>Group Maximum Duration :</b>	0
<b>Group Minimum Duration :</b>	180
<b>Show Attended Group? :</b>	No
<b>Edit Attended Group? :</b>	No
<b>Break time :</b>	0
<b>Group Marks :</b>	100

## DNB Pharmacology Paper1

<b>Section Id :</b>	3271872825
<b>Section Number :</b>	1
<b>Section type :</b>	Offline
<b>Mandatory or Optional :</b>	Mandatory
<b>Number of Questions :</b>	10
<b>Number of Questions to be attempted :</b>	10
<b>Section Marks :</b>	100
<b>Maximum Instruction Time :</b>	0
<b>Sub-Section Number :</b>	1
<b>Sub-Section Id :</b>	3271872829
<b>Question Shuffling Allowed :</b>	No

**Question Number : 1 Question Id : 32718734294 Question Type : SUBJECTIVE Consider As Subjective : Yes**

**Correct Marks : 10**

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. Define Pharmacovigilance. Describe Pharmacovigilance Programme of India. Discuss various challenges faced by this Programme. [2+5+3]

**Question Number : 2 Question Id : 32718734295 Question Type : SUBJECTIVE Consider As Subjective : Yes**

**Correct Marks : 10**

Define medication errors. What are the various types of medication errors? Discuss the strategies to prevent medication errors. [2+4+4]

**Question Number : 3 Question Id : 32718734296 Question Type : SUBJECTIVE Consider As Subjective : Yes**

**Correct Marks : 10**

What is plasma half-life of a drug? Discuss clinical importance of knowing plasma half-life of a drug. Write the differences between plasma half-life and biological half-life of a drug. [2+4+4]

**Question Number : 4 Question Id : 32718734297 Question Type : SUBJECTIVE Consider As Subjective : Yes**

**Correct Marks : 10**

Define the terms Bioavailability & Bioequivalence respectively. What are the guidelines for conduct of Bioavailability & Bioequivalence study of Investigational New Drug (IND) as per the "New Drugs & Clinical trials rules 2019"? [(2+2)+6]

**Question Number : 5 Question Id : 32718734298 Question Type : SUBJECTIVE Consider As Subjective : Yes**

**Correct Marks : 10**

Define Biosimilars. How are they different from Biological drugs? Describe the challenges for their use. [2+4+4]

**Question Number : 6 Question Id : 32718734299 Question Type : SUBJECTIVE Consider As Subjective : Yes**

**Correct Marks : 10**

a) Periodic safety update report (PSUR). [5]

b) Receptor regulation. [5]

**Question Number : 7 Question Id : 32718734300 Question Type : SUBJECTIVE Consider As Subjective : Yes**

**Correct Marks : 10**

Define the phenomenon of genetic polymorphism. Describe its role in clinical practice by giving suitable examples. [2+8]

**Question Number : 8 Question Id : 32718734301 Question Type : SUBJECTIVE Consider As Subjective : Yes**

**Correct Marks : 10**

What do you understand by Individualization of drug therapy? Enumerate the factors which influence action of various drugs. Discuss how pathological conditions affect the drug action. [3+3+4]

**Question Number : 9 Question Id : 32718734302 Question Type : SUBJECTIVE Consider As Subjective : Yes**

**Correct Marks : 10**

Compare & contrast between the following:

- a. Autoreceptors versus Heteroreceptors. [5]
- b. Drug specificity versus Drug selectivity. [5]

**Question Number : 10 Question Id : 32718734303 Question Type : SUBJECTIVE Consider As Subjective : Yes**

**Correct Marks : 10**

Define translational pharmacology. Describe the need of translational pharmacology. Discuss the challenges in translational research. [2+5+3]